Compare
Up to four compounds, side by side.
Search or pick a starting set. Differences light up so you can spot them fast.
Tirzepatide
1 / 4
Peptide
GLP-1 / GIP Dual Agonist
TirzepatideOverview
Summary
Dual-agonist successor to semaglutide — larger average weight loss in trials.
Category
GLP-1 / GIP Dual Agonist
Mechanism
Dual GLP-1 + GIP receptor agonist. Produces deeper appetite suppression and metabolic improvements than GLP-1 alone.
Effects
Top outcomes
- Fat loss96
- Inflammation55
Evidence
Established
Practical
Half-life
~5 days
Administration
subq
Risk
Legal status
rx only
Safety
GI side effects common. Same MTC warning as semaglutide.
Try a preset